The ROA for Thermo Fisher Scientific, Inc. tells us exactly what earnings were generated from the invested capital. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. Thermo Fisher Scientific makes up approx 2.36% of Banque Pictet Cie Sa’s portfolio.Denver Investment Advisors reduced its stake in TMO by selling 1,007 shares or 6.39% in the most recent quarter. The difference between the expected and actual EPS was $0.02/share, which represents an Earnings surprise of 1%. The Hedge Fund company now holds 8,915 shares of TMO which is valued at $1,404,202. NYSE exhibits a P/E ratio of 30.77 with a forward P/E of 17.13. The Hedge Fund company now holds 836,703 shares of TMO which is valued at $130,525,668. The premium would be too low to appeal to Illumina, he argued, and too expensive for Thermo Fisher. The heightened volatility saw the trading volume jump to 14,98,018 shares.
Advertisement
The consensus on Thermo Fisher Scientific Inc (TMO) based on 13 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. The company will report its next earnings on Oct 19 – Oct 24 (Est.). Overweight rating was given by 2 analysts and Underweight rating was given by 0 analysts.
The Company has received rating from WSJ analysts. The EPS growth for the past five (5) years shows a value of 15.00%, whilst the EPS value for the next five (5) years shows a figure of 10.47%.
While looking at the Stock’s Performance, Thermo Fisher Scientific Inc now shows a Weekly Performance of -0.27%, where Monthly Performance is -1.55%, Quarterly performance is 2.67%, 6 Months performance is 19.34% and yearly performance percentage is 27.59%.
Company latest quarter ended on 30 Jun 2016, company announced earnings of $0.66. An ROI of 7.00% for Thermo Fisher Scientific, Inc. evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.
Advertisement
Textron Inc. (NYSE:TXT) mean estimate for revenue for the ongoing quarter ending Sep 16 is $3.43B by 9 analysts. If Thermo Fisher Scientific increased its leverage ratio to 6x, we believe it could get down to 20% equity (but would lose its credit rating, which it has been reluctant to do), yet the deal would still be significantly dilutive due to higher interest expense. The firm operates through four divisions: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
